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Background: Low socioeconomic status, increasing age, and poor lifestyle behaviors are associated with poor 
survival in patients with oral cavity squamous cell carcinoma (OCSCC). To determine the overall survival (OS) 
and the risk of OCSCC death by tumor subsite.
Material and Methods: A retrospective cohort study of OCSCC patients diagnosed from 2007 to 2009 and treated 
at a single cancer center in Rio de Janeiro, Brazil. Patient information was obtained from the Hospital Cancer 
Registry (HCR) database and complemented by individual search of physical and electronic medical records. 
Descriptive statistics of population characteristics were computed. OS was estimated using the Kaplan-Meier 
method. Univariate and multivariate Cox proportional hazards regression analyses were used to estimate the risk 
of death by tumor subsite.
Results: Seven hundred and three patients with OCSCC were identified. Most patients were men (77.4%) with low 
levels of education (67.5%), who drank (73.9%) and smoked (79.7%). The most prevalent tumor site was the tongue 
(45.4%), 73.4% of patients had advanced (clinical stage III or IV) OCSCC at diagnosis and 74.1% died during 
follow-up. For the entire cohort, the OS was 39.1% at two years and 27.9% at five years. The median survival time 
was 1.4 years (95%CI: 1.2‒1.5). Non-operative treatment (HR: 3.11; 95%CI: 2.26‒4.29; p<0.001), advanced stage 
(HR 2.14; 95%CI 1.68-2.74; p<0.001), and age >60 years at diagnosis (HR: 1.37; 95%CI: 1.15‒1.64; p<0.001) were 
independently associated with the risk of death. However, these factors varied by tumour subsite.
Conclusion: Analysis of specific subsites of the oral cavity revealed substantial differences in prognostic factors 
associated with poor survival in OCSCC.
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Introduction
Oral cavity cancer (OCC) is among the most com-
mon types of cancer worldwide. In 2018, there were 
an estimated 354,864 new cases of OCC worldwide. 
Age-adjusted incidence rates were estimated at 5.8 per 
100,000 men and 2.3 per 100,000 women, whereas ad-
justed mortality rates were estimated at 2.8 per 100,000 
in men and 1.2 per 100,000 in women (1). In Brazil, oral 
cancer is the 7th most incident cancer in the general 
population, corresponding to a risk of 14.14 new cases 
per 100,000 (2). Between 2002 and 2013, the adjusted 
mortality coefficient presented stability in both men and 
women with an average rate of 1.87 per 100,000 inhabit-
ants (3).
Squamous cell carcinoma (SCC) is the most common 
histologic type of OCC. As with most cancers, the stage 
at diagnosis of OCC is highly correlated with the like-
lihood of survival. However, only 31% of OCC cases 
are diagnosed at an early stage, when five-year overall 
survival rates may reach 80% (4,5). However, when di-
agnosed at a late stage, five-year overall survival ranges 
from 30% to 50% (5).
In patients with oral cavity squamous cell carcinoma 
(OCSCC), the main prognostic factors associated with 
poor survival are age ≥ 60 years, male gender, race/skin 
color other than white, advanced stage disease at diag-
nosis, non-eligibility for surgery, and local recurrence 
(6-9). However, prognostic factors may vary in impor-
tance by tumor subsite. To the best of our knowledge, no 
studies so far have examined the prognostic factors of 
OCSCC located in distinct subsites of the oral cavity in 
Brazil. Thus, this study aimed to identify the prognostic 
factors associated with poor survival by tumor subsite 
in Brazilian patients diagnosed with OCSCC.
Material and Methods
This is a retrospective cohort study of patients with OC-
SCC diagnosed and treated at the Cancer Hospital I of 
the Brazilian National Cancer Institute (HCI/INCA), 
Rio de Janeiro, Brazil between January 1, 2007 and De-
cember 31, 2009. Tumor subsites were defined accord-
ing to the International Classification of Diseases for 
Oncology, third edition (ICD-O-3) as follows: tongue 
(C02, C02.0, C02.1, C02.2, C02.3, C02.4, C02.8, C02.9); 
gum (C03, C03.0, C03.1, C03.9); floor of mouth (C04, 
C04.0, C04.1, C04.8, C04.9); palate (C05, C05.0, C05.1, 
C05.2, C05.8, C05.9); and other and unspecified parts 
of mouth (C06, C06.0, C06.1, C06.2, C06.8, C06.9). Pa-
tients with tumors of the lip (C00, C00.0, C00.1, C00.2, 
C00.3, C00.4, C00.5, C00.6, C00.8, C00.9) were not in-
cluded because of their different risk factors and prog-
nosis. Patients under 18 years of age and patients with 
synchronous tumors were excluded from the analysis.
Patients were selected from the HCI/INCA Hospital 
Cancer Registry (HCR). All cases registered between 
2007 and 2009 were examined to ensure that patients 
were followed for at least five years for the calculation 
of survival probabilities.
Patient information was obtained from the HCR data-
base and complemented by individual search of physi-
cal and electronic medical records when needed. De-
spite efforts, a proportion of patients remain without 
valid information for some important variables, due to 
under-registration, errors in the coding of data, misclas-
sification or inconsistencies. The Brazilian Mortality 
Information System was consulted for all patients lost 
to follow-up.
The five-year overall survival (OS) rate was the primary 
outcome (dependent variable), defined as the time inter-
val in years between the date of diagnosis and the date 
of death from any cause. Patients lost to follow-up were 
censored at the time of the last HCI/INCA visit.
The independent variables and descriptors examined 
were gender, age, alcohol use (never drinker, current 
drinker, former drinker), smoking (never smoker, cur-
rent smoker, former smoker), race/skin color (classified 
as white, black, yellow, brown, indigenous according 
to the Brazilian Institute of Geography and Statistics 
[IBGE]), clinical stage, tumor size, number of positive 
lymph nodes, education, tumor-free resection margins, 
extracapsular spread, grade, tumor topography and 
morphology, and treatment.
- Statistical analysis
Continuous variables are presented as mean ± standard 
deviation (SD) whereas categorical variables are pre-
sented as frequency distribution. Overall survival was 
estimated using the Kaplan-Meier method and differ-
ences between exposure groups were estimated by us-
ing the log-rank test. Univariate and multivariate Cox 
proportional hazards regression analyses were used to 
estimate the risk of death by tumor subsite. Variables 
with a significance level of P < 0.20 on the univariate 
analysis were included in the multivariate models by 
stepwise forward selection with the entry order based 
on their level of significance. Variables of clinical 
and epidemiological importance were included in the 
model irrespective of the level of significance on the 
univariate analysis. The data were entered into an Ex-
cel spreadsheet (Microsoft, Redmond, WA, USA) and 
all analyses were performed using SPSS Statistics for 
Windows, version 23.0 software (IBM Corp., Armonk, 
NY, USA).
This study was approved by the institutional Research 
Ethics Committee under protocol numbers 128/11, 
CAAE 0104.0.007.000-11, on October 21 2011.
Results
Of the 703 patients identified, 77.4% were men, 56.8% 
were aged under 60 years (mean ± SD = 59.03 ± 11.89 
yr.), 62.0% were white, 67.5 % had less than eight years 
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of education, 79.7% were smokers at diagnosis, 73.9% 
were drinkers, 73.4% had advanced (clinical stage III or 
IV) OCSCC, and 74.1% of patients died during follow-
up. Three hundred and seven patients (43.7%) under-
went surgery, either alone or in combination with other 
therapies. Of these, 82.7% underwent cervical lymphad-
enectomy and 89.1% had tumor-free resection margins 
(Table 1).
During the follow-up period, 521 (74.1%) patients died, 
43 (8.3%) dying of non-cancer causes. The calculated 
overall survival of the cohort was 39.1% at two years 
and 27.9% at five years (Fig. 1 and Fig. 2). The median 
survival time was estimated to be 1.4 years (95% CI: 
1.2‒1.5). Results of overall survival analysis by tumor 
subsite are presented in Table 2. The variables associ-
ated with the risk of death are shown in Table 3.









na (%) na (%) na (%) na (%) na (%) na (%)
Gender
Male 544 (77.4) 143 (83.1) 268 (77.5) 52 (65.0) 34 (82.9) 47 (73.4)
Female 159 (22.6) 29 (16.9) 78 (22.5) 28 (35.0) 7 (17.1) 17 (26.6)
Age
<60 years 399 (56.8) 104 (60.5) 213 (61.6) 37 (46.2) 18 (43.9) 27 (42.2)
≥60 years 304 (43.2) 68 (39.5) 133 (38.4) 43 (53.8) 23 (56.1) 37 (57.8)
Race/Skin color
White 436 (62.0) 92 (53.5) 225 (65.0) 48 (60.0) 24 (58.5) 47 (73.4)
No white 267 (38.0) 80 (46.5) 121 (35.0) 32 (40.0) 17 (41.5) 17 (26.6) 
Education
< 8 years 467 (67.5) 116 (68.6) 227 (66.8) 58 (73.4) 30 (73.2) 36 (57.1)
≥ 8 years 225 (32.5) 53 (31.4) 113 (33.2) 21 (26.6) 11 (26.8) 27 (42.9)
Smoking
Never smoking 74 (11.1) 8 (4.9) 41 (12.3) 14 (19.2) 1 (2.6) 10 (15.9)
Former smoker 62 (9.3) 17 (10.4) 27 (8.1) 4 (5.5) 3 (7.9) 11 (17.5)
Current smoker 533 (79.7) 138 (84.7) 264 (79.5) 55 (75.3) 34 (89.5) 42 (66.7)
Alcohol use
Never drinker 117 (17.6) 17 (10.4) 63 (19.1) 22 (30.1) 4 (10.5) 11 (17.7)
Former drinker 57 (8.6) 14 (8.6) 26 (7.9) 5 (6.8) 4 (10.5) 8 (12.9)
Current drinker 492 (73.9) 132 (81.0) 241 (73.0) 46 (63.0) 30 (78.9) 43 (69.4)
Clinical Stage
I-II 187 (26.6) 38 (22.2) 98 (28.3) 15 (18.8) 15 (36.6) 21 (32.8)
III-IV 515 (73.4) 133 (77.8) 248 (71.7) 65 (81.2) 26 (63.4) 43 (67.2)
Death
Yes 521 (74.1) 132 (76.7) 251 (72.5) 62 (77.5) 31 (75.6) 45 (70.3)
No 182 (25.9) 40 (23.3) 95 (27.5) 18 (22.5) 10 (24.4) 19 (29.7)
Surgery
Isolated 114 (16.2) 30 (17.4) 60 (17.3) 12 (15.0) 2 (4.9) 10 (15.6)
Associated with another treatment 193 (27.5) 46 (26.7) 94 (27.2) 33 (41.2) 1 (2.4) 19 (29.7)
Not performed 396 (56.3) 96 (55.8) 192 (55.5) 35 (43.8) 38 (92.7) 35 (54.7)
Cervical lymphadenectomyc
Yes 254 (82.7) 65 (85.5) 131 (85.1) 35 (85.4) 1 (33.3) 23 (85.2)
No 53 (17.3) 11 (14.5) 23 (14.9) 06 (14.8) 2 (66.7) 4 (14.8)
Free marginsc
Yes 254 (89.1) 65 (90.3) 128 (90.1) 32 (84.2) 3 (100) 26 (86.7)
No 31 (10.9) 7 (9.7) 14 (9.9) 6 (15.8) 0  4 (13.3)
Histological grade
Low 45 (7.2) 10 (6.7) 26 (8.2) 2 (2.9) 6 (15.8) 1 (1.8)
Intermediary 486 (77.3) 129 (86.6) 236 (74.4)  50 (71.4) 26 (68.4) 45 (81.8)
High 98 (15.6) 10 (6.7) 55 (17.4) 18 (25.7) 6 (15.8)  9 (16.4)
a Valid data only; b Jugal mucosa (n=31) and retromolar trigone (n=33); c Only patients who underwent surgery;
Missing values: education (11; 1.6%), smoking (34; 4.8%), alcohol use (37; 5.3%), clinical stage (1; 0,1%), free margins (22; 3.1%) and histological 
grade (74; 10.5%).
Table 1: Sociodemographic and clinical characteristics of the study population (n=703).
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Male 1.3 (1.2-1.5) 1.1 (0.9-1.3) 1.3 (1.1-1.5) 1.1 (0.9-1.1) 1.7 (0.8-2.7)a 1.9 (1.4-2.4)
Female 1.6 (1.1-2.1) 2.5 (1.4-3.6) 1.3 (0.5-2.3) 1.5 (0.8-2.2) 0.8 (0.3-1.5) 1.3 (0.6-2.4)
Race/Skin color
White 1.4 (1.2-1.7)a 1.2 (1.0-1.5) 1.4 (1.1-1.8)a 1.3 (0.7-2.0) 1.6 (0.5-2.8) 2.0 (1.4-2.7)
No white 1.2 (1.2-1.5) 1.3 (0.9-1.9) 1.1 (0.9-1.3) 1.1 (0.7-1.6) 2.0 (0.8-3.3) 1.2 (0.2-2.2)
Education
< 8 years of study 1.3 (1.1-1.4)a 1.2 (1.0-1.5) 1.3 (1.1-1.5) 1.0 (0.8-1.4) 1.2 (0.2-2.2) 1.8 (1.3-2.3)
≥ 8 years of study 1.7 (1.4-2.1) 1.5 (0.4-2.6) 1.4 (0.8-2.0) 1.9 (1.3-2.5) 3.4 (1.0-2.3) 1.7 (0.6-2.9)
Age
≥ 60 years 1.3 (1.1-1.5) 1.3 (1.0-1.7) 1.4 (1.1-1.8)a 1.1 (0.8-1.5) 1.3 (0.4-2.2) 1.7 (0.8-2.7)
< 60 years 1.4 (1.2-1.5) 1.1 (0.7-1.5) 1.1 (0.8-1.3) 1.3 (0.6-2.1) 2.0 (0.6-3.5) 2.1 (0.7-3.5)
Alcohol use
Nerver drinker 1.8 (1.2-2.4) 2.2 (0.4-4.1) 1.9 (0.1-3.8)a 1.8 (0.5-3.2) 0.6 (0.2-1.1)a 1.0 (0.4-1.7)
Current and former 
drinker 1.3 (1.2-1.2) 1.2 (1.0-1.5) 1.3 (1.1-1.5) 1.1 (0.8-1.5) 1.7 (0.8-2.7) 2.1 (1.0-3.2)
Smoking
Never smoker 2.3 (0-4.9)a 1.4 (0-3.6) 5.0 (0.1-10.0)a 1.0 (0-3.0) 1.7 (e) 1.5 (0.7-2.3)
Current and former 
smoker 1.3 (1.2-1.4) 1.2 (1.0-1.6) 1.3 (1.2-1.5) 1.3 (0.9-1.6) 1.6 (0.9-2.4) 1.9 (1.4-2.4)
Clinical stage
I-II 7.2 (5.2-9.4)a 7.3 (5.5-9.2)a 7.2 (4.0-10.5)a 4.7 (2.9-6.5)a 4.2 (0-9.1)a 3.1 (e)a
III-IV 1.0 (0.9-1.1) 1.0 (0.8-1.2) 1.0 (0.9-1.2) 1.0 (0.8-1.4) 0.8 (0.3-1.5) 1.3 (0.6-2.1)
Surgery
Isolated 7.3 (4.9-9.8)a 7.3 (4.4-10.2)a 7.9 (5.4-10.3)a 4.1 (e)a 0.6 (e) 1.7 (0-3.7)
Associated with another 
tratment 4.0 (2.4-5.8) 4.4 (0.6-8,3) 4.3 (2.0-6.7) 3.2 (1.5-5.0) 6.1 (
e) 4.0 (1.7-6.5)
Not performed 0.8 (0.8-0.9) 0.8 (0.7-0.9) 0.8 (0.7-0.9) 0.7 (0.6-0.9) 1.6 (1.1-2.1) 1.1 (0.4-1.9)
Histological grade
Low and intermediary 1.3 (1.2-1.5)a 1.3 (1.0-1.6) 1.2 (1.1-1.4)a 1.2 (0.8-1.7) 1.6 (0.5-2.8) 2.0 (0.9-3.15)
High 1.3 (0.9-1.7) 0.8 (0.6-1.1) 1.5 (0-7.0) 1.3 (0.4-2.3) 0.9 (0.2-1.7) 1.1 (0-2.62)
Cervical lymphadenectomyc
No d 3.6 (2.4-4-9) d d 6.1 (e) d
Yes 4.3 (2.3-6.3)a 6.5 (3.7-9.5) 4.4 (1.2-7.7) 0.9 (1.5-5.1) 0.6 (e) 2.8 (1.1-4.4)
Free marginsc
No 4.3 (1.4-7.3) 8.0 (e) 2.6 (0-8.1) 3.2 (0-8.9) d 2.1 (0-5.2)
Yes 6.1 (4.3-7.8) 5.3 (1.8-8.8) 7.2 (5.2-9.3) 4.1 (0.8-7.4) 4.2 (2.5-5.9) 3.1 (0.2-6.2)
a p < 0.05; b Jugal mucosa and retromolar trigone; c Only patients who underwent surgery; d Did not reach the median; e Unavailable
CI= confidence interval
Table 2: Median survival (years) for patients diagnosed with SCC (n=703).
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HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Gender
Male 1 1 1 1 1 1
Female 0.81 (0.7-1.0) 1.4 (0.9-2.2) 1.3 (1.0-1.8) 1.2 (0.6-2.0) 0.4 (0.1-1.0) 1.0 (0.5-2.0)
Race/Skin color
White 1 1 1 1 1 1
No white 1.2 (1.0-1.4)a 1.1 (0.7-1.5) 1.3 (1.0-1.7)a 1.2 (0.7-2.0) 0.7 (03.-1.4) 1.4 (0.8-2.8)
Education
< 8 years of study 1 1 1 1 1 1
≥ 8 years of study 0.8 (0.6-0.9)a 1.2 (0.8-1.8) 0.8 (0.6-1.0) 1.4 (0.8-2.6) 2.0 (0.9-5.0) 0.9 (0.5-1.6)
Age
≥ 60 years 1 1 1 1 1 1
< 60 years 0.9 (0.7-1.0) 1.3 (0.9-1.8) 1.3 (1.1-1.7)a 0.9 (0.6-1.6) 0.7 (0.3-1.5) 0.7 (0.4-1.3)
Alcohol use
Nerver drinker 1 1 1 1 1 1
Current and former 
drinker
1.2 (0.9-1.6) 1.3 (0.7-2.4) 1.5 (1.0-2.2)a 1.2 (0.7-2.2) 0.3 (0.9-0.9)a 0.6 (0.3-1.2)
Smoking
Never smoker 1 1 1 1 1 1
Current and former 
smoker
1.5 (1.0-2.0)a 1.2 (0.5-3.0) 1.8 (1.1-2.8)a 1.3 (0.6-2.6) 0.8 (0.1-5.9) 1.0 (0.5-2.3)
Clinical stage
I-II 1 1 1 1 1 1
III-IV 2.9 (2.3-3.7)a 4.5 (2.6-7.7)a 2.9 (2.1-4.0)a 2.2 (1.1-4.6)a 2.5 (1.1-5.6)a 2.0 (1.0-4.0)
Histological grade
Low and intermediary 1 1 1 1 1 1
High 0.7 (0.6-1.0)a 1.0 (0.5-2.3) 0.6 (0.4-0.8)a 1.0 (0.5-1.8) 1.7 (0.6-4.6) 1.2 (0.5-3.0)
Cervical lymphadenectomy
Yes 1 1 1 1 1 1
No 0.6 (0.4-0.9)a 1.3 (0.6-2.9) 0.4 (0.1-0.8)a 0.8 (0.3-1.9) c 0.3 (0.4-2.1)
Free margins
Yes 1 1 1 1 1 1
No 0.7 (0.5-1.2) 0.8 (0.3-2.4) 1.5 (0.8-3.0) 1.2 (0.4-3.2) c 1.3 (0.4-4.5)
Surgery
Isolated 1 1 1 1 1 1
Associated with 
another treatment
1.3 (0.9-1.8) 1.3 (0.7-2.5) 1.6 (1.0-2.7)a 0.9 (0.4-2.3) 0.4(0.2-6.9) 0.6 (0.2-1.5)
Not performed 4.4 (3.3-6.0)a 6.8 (3.8-12.2)a 6.0 (3.9-9.4)a 5.2 (2.1-13.0)a 0.7 (0.9-5.3) 1.3 (0.5-3.0)
a p < 0,05; b Jugal mucosa and retromolar trigone; c Unavailable
Table 3: Factors associated with overall survival in patients with SCC (n=703).
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Fig. 1: Overall survival of patients with oral cavity squamous cell 
carcinoma: all patients
The variables independently associated with OCSCC 
death by tumor subsite are presented in Table 4.




Associated with another tratment 1.00 0.71-1.40 0.995
Not performedb 3.11 2.26-4.29 <0.001
Clinical Stage
I/II 1
III/IV 2.14 1.68-2.74 <0.001
Age
<60 years 1
 ≥60 years 1.37 1.15-1.64 <0.001
SCC floor of mouth
Clinical Stage
I/II 1
III/IV 2.43 1.33-4.45 0.004
Surgery
Isolated 1
Associated with another tratment 0.93 0.48-1.84 0.855
Not performedb 4.39 2.27-8.50 <0.001
Age
<60 years 1
 ≥60 years 1.55 1.09-2.22 0.014
SCC tongue and border of tongue
Surgery
Isolated 1
Associated with another tratment 1.44 0.87-2.38 0,154
Not performedb 4.73 2.89-7.77 <0.001
Age
<60 years 1
≥60 years 1.54 1.19-2.00 0.001
Clinical Stage
I/II 1
 III/IV 1.61 1.12-2.32 0.010
SCC gun, gingival ridge and ridge alveolar
Surgery        
Isolated 1
Associated with another tratment 0.92 0.37-2.29 0.858




III/IV 4.28 1.78-10.26 0.001
Gender
Female 1
Male 3.31 1.23-8.87 0.017
Education
≥8 years 1
<8 years 3.14 1.24-7.98 0.016
a Statistics were calculated excluding patients with missing data.
b Received other treatment modalities or no treatment.
HR= hazard ratio; CI= confidence interval; SCC= squamous cell carcinoma
Table 4: Independent prognostic factors for death of OCSCC patients.
Fig. 2: Overall survival of patients with oral cavity squamous cell 
carcinoma: by tumor subsite.
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reasons for this may be related to the presence of comor-
bidities that would contraindicate them from surgery, 
treatment refusal or being treated in centres that are less 
likely to recommend surgery due to age, leading to an 
undertreated elderly population (12).
Gourin and Podolsky, in 2006, identified 1,128 patients 
diagnosed with head and neck SCC from 1985 to 2002 
in Georgia, USA and showed that black race/skin color, 
advanced TNM stage, 2‒3 comorbidities, inoperable 
disease, and tumor subsite were associated with poor-
er overall survival (13). In the current study, stage III 
and IV disease (SCC of the floor of mouth, tongue and 
border of tongue, hard palate and nonoperative treat-
ment (SCC of the floor of mouth, tongue and border of 
tongue, gum, gingival ridge, and alveolar ridge mucosa) 
were associated with poor survival.
In a study that investigated the effect of race and gender 
on long-term survival of oral and oropharyngeal can-
cer in 22,162 patients identified in the US Surveillance, 
Epidemiology and End Results (SEER) database from 
1975 to 1986, Osazuwa-Peters et al. reported that black 
race/skin color, male gender, low socioeconomic status, 
living without a partner, advanced stage disease at diag-
nosis, and nonoperative treatment were associated with 
the poorest overall survival rates; in their study, tumor 
subsite was also associated with survival (14). Similar-
ly, in the current study, men (SCC of the hard palate), 
patients with advanced stage disease (SCC of the floor 
of mouth, tongue and border of tongue, hard palate), 
and those who received nonsurgical treatment (SCC of 
the floor of mouth, tongue and border of tongue, gum, 
gingival ridge, and alveolar ridge mucosa) had poorer 
survival. In contrast, race/skin color did not influence 
survival.
Van Dijk et al., in 2016, identified 13,108 patients diag-
nosed with OCSCC in The Netherlands from 1991 to 
2010 and found that male gender, older age, advanced 
stage disease, nonoperative treatment, and late treat-
ment were significantly associated with poor five-year 
overall survival in OCSCC patients. In addition, overall 
survival varied by tumor subsite (8). Similarly, in the 
current study, male gender (SCC of the hard palate), 
older age (SCC of the floor of mouth, tongue and border 
of tongue), advanced stage disease (SCC of the floor of 
mouth, tongue and border of tongue, hard palate), and 
nonoperative treatment (SCC of the floor of mouth and 
gum, tongue and border of tongue, gingival ridge, and 
alveolar ridge mucosa) were associated with poor sur-
vival.
In a retrospective study of 2,738 patients who received 
treatment between 1990 and 2011 at seven international 
cancer centers, Amit et al. reported that surgery after 
2000, negative tumor margins, adjuvant therapy, and 
early stage disease were independent predictors of bet-
ter five-year overall survival (7). Similarly, in our study 
For the overall cohort, nonoperative treatment (HR 3.11; 
95%CI 2.26-4.29; p<0.001), advanced stage (HR 2.14; 
95%CI 1.68-2.74; p<0.001), and age > 60 years at diag-
nosis (HR 1.37; 95%CI 1.15-1.64; p<0.001) were inde-
pendently associated with the risk of death. Advanced 
stage (HR 2.43; 95%CI 1.33-4.45; p= 0.004), nonopera-
tive treatment (HR 4.39; 95%CI 2.27-8.50; p<0.001), 
and age > 60 years at diagnosis (HR 1.55; 95%CI 1.09-
2.22; p= 0.014) were independently associated with the 
risk of death for floor of mouth tumors, whereas nonop-
erative treatment (HR 4.73; 95%CI 2.89-7.77; p<0001), 
age > 60 years (HR 1.53; 95%CI 1.19-2.00; p= 0.001) 
and advanced stage (HR 1.61; 95%CI 1.12-2.32; p= 
0.010) were independently associated with the risk of 
death for tongue and border of tongue tumors. In ad-
dition, nonoperative treatment (HR 5.18; 95%CI 2.08-
13.0; p<0001) was independently associated with the 
risk of death for gum and gingival ridge tumors. For 
hard palate tumors, advanced stage (HR 4.28; 95%CI 
1.78-10.26; p= 0.001), male gender (HR 3.31; 95%CI 
1.23-8.87; p= 0.017), and < eight years of education (HR 
3.14; 95%CI 1.24-7.98; p= 0.016) were independently 
associated with the risk of death. Lastly, multivariate 
analysis was not performed for jugal mucosa and retro-
molar trigone because no variables were significant on 
the univariate analysis.
Discussion
In this study, 703 patients with OCSCC who were treat-
ed at a single cancer center in Brazil were retrospec-
tively identified. Most patients were men with low level 
of education who smoked and drank. The most preva-
lent tumor site was the tongue (49.2%). More than 2/3 of 
patients were diagnosed at an advanced stage and died 
during follow-up. Nonoperative treatment, advanced 
stage, and age > 60 years at diagnosis were indepen-
dently associated with the risk of death. However, these 
factors varied by tumor subsite.
Surgery remains the most important curative treat-
ment modality that impacts on the prognosis of oral 
neoplasms. The reasons why patients are not submit-
ted to surgery may be related to primary radiotherapy 
treatment, comorbidities that would prevent surgery, 
the presentation of unresectable/incurable (advanced 
staging) disease or patient preference (8). The progno-
sis for early-stage disease is relatively good, but 40 to 
60% of patients have advanced-stage disease at diag-
nosis (10). If cancer is diagnosed and treated early, the 
risk of micrometastatic spread of disease and treatment-
related morbidity decreases. In addition, patients with 
advanced-stage oral cancer have significantly worse 
health-related quality-of-life scores compared to pa-
tients treated for early-stage disease (11). Elderly people 
are significantly less likely to undergo oral cavity resec-
tion despite the increased incidence in this group. The 
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advanced stage disease was associated with poor prog-
nosis in cases of SCC of the floor of mouth, tongue and 
border of tongue, and hard palate.
In a retrospective study that identified 909 patients with 
SCC of the oral cavity and pharynx treated at the M. 
D. Anderson Cancer Center from 1984 to 1993, Moore 
et al. reported that patients 60 years of age and older, 
African-Americans, and those who received nonsur-
gical treatment had a higher risk of dying (6). Similar 
results were observed in the current study for patients 
with SCC of the floor of mouth (age and treatment mo-
dality), tongue and border of tongue (age and treatment 
modality), and gum, gingival ridge and alveolar ridge 
mucosa (treatment modality).
To our knowledge, only two studies have examined the 
independent prognostic factors for survival in specific 
subsites of the oral cavity (15,16). In a study that de-
scribed the incidence and determinants of survival of 
1,489 patients with SCC of the hard palate between 1973 
and 2014 using the SEER database, Alonso et al. found 
that advanced age, nonoperative treatment, radiation 
therapy, tumor stage and grade were independently as-
sociated with worse overall survival (15). In the current 
study, in addition to tumor stage, male gender and low 
education level were also independently associated with 
poor survival in patients with SCC of the hard palate.
In a study that examined the survival of 62 patients with 
tongue cancer who received treatment between 2009 
and 2012 in Indonesia, Sutandyo et al. reported that 
stage T3/T4 tumors were associated with a significant-
ly increased risk of death compared to T1/T2 tumors. 
However, in their study, stage was not significantly as-
sociated with overall survival (16). Contrarily, stage III 
and IV disease was associated with an increased risk of 
death in our study, even though independent factors as-
sociated with the risk of death identified in our sample 
such as age ≥ 60 years was not investigated by Sutandyo 
et al. (16).
Limitations of this study include its retrospective sec-
ondary nature and the number of patients with missing 
data for some variables, which was ameliorated by the 
search of physical and electronic medical records. How-
ever, the authors assumed that the small percentage of 
missing data (< 5%, except for histological grade) did 
not bias the results. Moreover, prognostic factors for 
OCSCC including surgical (reconstructive technique, 
tracheostomy) and clinical (body mass index, albumin 
and hematocrit levels, Human Papilloma Virus [HPV] 
and Epstein-Barr virus [EBV] infections) parameters, 
tumor histology (histologic type, perineural invasion, 
lymphovascular invasion, lymph node positivity), and 
tumor markers (Ki67, epidermal growth factor recep-
tor [EGFR], interleukin-2) were not examined. In ad-
dition, the small sample size for the Gum/Gingival 
ridge and alveolar ridge (n=74), Hard palate (n=41) and 
Others (n=64) may not have sufficient power to detect 
differences between categories as being statistically 
significant (type II error). Nevertheless, a strength of 
this study is that it is the first to explicitly examine the 
prognostic factors associated with overall survival in 
OCSCC stratified by tumor subsite in a Brazilian popu-
lation from a single cancer center.
Conclusions
In this study, different independent prognostic factors 
were associated with the risk of OCSCC death depend-
ing on tumor subsite. Tumor stage was not an indepen-
dent predictor of death only in SCC of the gum, gingi-
val ridge, and alveolar ridge. Surgical treatment was an 
independent predictor of death in SCC of the floor of 
mouth, tongue, and gum. It should be noted that tumor 
staging at diagnosis is essential in deciding appropri-
ate treatment. In addition, age > 60 years was associ-
ated with risk of death in SCC of the floor of mouth 
and tongue/border of tongue. In the latter tumors, race/
skin color other than white was also associated with 
poor survival. Finally, male gender and < eight years of 
education were independent predictors of death in SCC 
of the hard palate.
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